About Prolacta Bioscience
Prolacta Bioscience is a company based in Los Angeles (United States) founded in 1999.. Prolacta Bioscience has raised $98.72 million across 10 funding rounds from investors including PROOF, Aisling Capital and Health Evolution Partners. Prolacta Bioscience operates in a competitive market with competitors including Beingmate Baby Child Food, BoobyBiome, Lowenzahn Organics, Wellements and Pharmacia Laboratorij, among others.
- Headquarter Los Angeles, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$98.72 M (USD)
in 10 rounds
-
Latest Funding Round
$9 M (USD), Series E
May 14, 2018
-
Investors
PROOF
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Prolacta Bioscience
Prolacta Bioscience has successfully raised a total of $98.72M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $9 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series E — $9.0M
-
First Round
First Round
(23 Jun 2004)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2018 | Amount | Series E - Prolacta Bioscience | Valuation |
investors |
|
| May, 2017 | Amount | Series E - Prolacta Bioscience | Valuation | PROOF |
|
| Dec, 2016 | Amount | Series E - Prolacta Bioscience | Valuation | EW Healthcare Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Prolacta Bioscience
Prolacta Bioscience has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include PROOF, Aisling Capital and Health Evolution Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage technology companies are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Prolacta Bioscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Prolacta Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Prolacta Bioscience Comparisons
Competitors of Prolacta Bioscience
Prolacta Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beingmate Baby Child Food, BoobyBiome, Lowenzahn Organics, Wellements and Pharmacia Laboratorij, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of nutrition products for babies and children
|
|
| domain | founded_year | HQ Location |
Developer of probiotic supplement for babies
|
|
| domain | founded_year | HQ Location |
Food supplements for babies' growth and development are provided.
|
|
| domain | founded_year | HQ Location |
Organic baby wellness products and supplements are manufactured for infants.
|
|
| domain | founded_year | HQ Location |
Provides comprehensive baby formula products for infants and toddlers.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Prolacta Bioscience
Frequently Asked Questions about Prolacta Bioscience
When was Prolacta Bioscience founded?
Prolacta Bioscience was founded in 1999 and raised its 1st funding round 5 years after it was founded.
Where is Prolacta Bioscience located?
Prolacta Bioscience is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Is Prolacta Bioscience a funded company?
Prolacta Bioscience is a funded company, having raised a total of $98.72M across 10 funding rounds to date. The company's 1st funding round was a Series E of $35M, raised on Jun 23, 2004.
What does Prolacta Bioscience do?
Founded in 1999 and based in Los Angeles, United States, Prolacta Bioscience operates in the biotechnology sector focused on neonatal nutrition. Standardized formulations derived from donated human breast milk are produced for premature infants in neonatal intensive care units. Surplus milk is sourced through affiliate milk banks. Key products include Prolact, Premielact Prolact HM, Prolact CR, and Prolact RTF, with clinical studies indicating improved health outcomes.
Who are the top competitors of Prolacta Bioscience?
Prolacta Bioscience's top competitors include Beingmate Baby Child Food, BoobyBiome and Lowenzahn Organics.
Who are Prolacta Bioscience's investors?
Prolacta Bioscience has 13 investors. Key investors include PROOF, Aisling Capital, Health Evolution Partners, EW Healthcare Partners, and Alta Partners.